Infectious Disease Diagnosis Is Changing — From Guesswork to Precision

main_260505_083612.pdf

Download PDF • 436KB

A recent review published in The Lancet Infectious Diseases highlights how clinical metagenomic testing (mNGS) is transforming infectious disease management by enabling the detection of all known and novel pathogens in a single unbiased assay—without needing prior assumptions about the causative agent.

Across 103 prospective studies, the strongest evidence was seen in:

✔ Lower respiratory tract infections

✔ Sepsis

✔ CNS infections

✔ Fever of unknown origin

✔ Febbrile neutropenia

The most impactful clinical outcomes included:

🔹 Earlier and more accurate pathogen detection

🔹 De-escalation of unnecessary broad-spectrum antibiotics

🔹 Faster escalation when resistant pathogens were identified

🔹 Better infection control interventions

🔹 Earlier initiation of immunomodulatory treatment

🔹 Improved differentiation between infection, inflammation, and even malignancy

Particularly in ICU settings, mNGS showed strong value in rapidly screening critically ill patients where every hour matters. In some studies, antimicrobial treatment changed in up to 35% of patients, with improved clinical outcomes and shorter time to diagnosis.

However, the paper also reminds us: mNGS is powerful—but not magic. Clinical utility depends heavily on:

• Proper patient selection

• Turnaround time

• DNA + RNA sequencing capability

• Interpretation expertise

• Integration with conventional microbiology

• Avoiding false positives and overtreatment

This is where quality matters.

At AGTC Genomics, we strongly believe that metagenomics should not simply be about sequencing more—it must be about delivering clinically actionable answers.

The future of infectious disease diagnostics is not just faster testing.

It is:

👉 Right Sample

👉 Right Technology

👉 Right Interpretation

👉 Right Clinical Decision

Because precision medicine begins with precision diagnosis.